2,242
Views
11
CrossRef citations to date
0
Altmetric
Original Articles

Enhanced dissolution characteristics of piroxicam–Soluplus® nanosuspensions

, , , &
Pages 916-929 | Received 05 Oct 2015, Accepted 10 Apr 2016, Published online: 13 May 2016

Figures & data

Table 1. Mathematical models used to predict drug release mechanism.

Figure 1. Phase solubility of piroxicam in different concentrations of the polymer Soluplus®.

Figure 1. Phase solubility of piroxicam in different concentrations of the polymer Soluplus®.

Figure 2. Gibbs free energy of transfer values with increasing Soluplus concentrations.

Figure 2. Gibbs free energy of transfer values with increasing Soluplus concentrations.

Figure 3. Overlay of the PXRD patterns of piroxicam, Soluplus® and the nanoformulations.

Figure 3. Overlay of the PXRD patterns of piroxicam, Soluplus® and the nanoformulations.

Figure 4. Overlay of the thermal analysis curves of piroxicam, Soluplus® and the nanoformulations.

Figure 4. Overlay of the thermal analysis curves of piroxicam, Soluplus® and the nanoformulations.

Figure 5. Overlay of FTIR spectra of piroxicam, Soluplus® and the nanoformulations.

Figure 5. Overlay of FTIR spectra of piroxicam, Soluplus® and the nanoformulations.

Figure 6. FESEM images of Piroxicam Soluplus Nanoformulations of ratios 2:1 (above) and 1:1 (Below) after 6 hours of milling.

Figure 6. FESEM images of Piroxicam Soluplus Nanoformulations of ratios 2:1 (above) and 1:1 (Below) after 6 hours of milling.

Figure 7. Caco-2 cell viability after exposure to various concentrations of Soluplus® and the nanoformulations (NS PS 1:1 and 1:4 for 12 hours). Significantly different with respect to control: *p < 0.05, #p < 0.05.

Figure 7. Caco-2 cell viability after exposure to various concentrations of Soluplus® and the nanoformulations (NS PS 1:1 and 1:4 for 12 hours). Significantly different with respect to control: *p < 0.05, #p < 0.05.

Figure 8. Dissolution analysis of the nanoformulations in comparison of the pure drug.

Figure 8. Dissolution analysis of the nanoformulations in comparison of the pure drug.

Table 2. Dissolution efficiencies achieved with varying polymer content in the formulations.

Table 3. Statistical parameters obtained after fitting the drug release data to various release kinetic models.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.